Treatment of cutaneous lupus erythematosus with etretinate.
Nineteen patients with different clinical subsets of cutaneous lupus erythematosus (LE) were treated with the aromatic retinoid etretinate. In 11 of them excellent or good treatment results were obtained within two to six weeks. Best response to etretinate therapy was seen in male patients with discoid lupus erythematosus. Etretinate should prove a valuable drug in LE therapy.
T
T
Ruzicka
M
M
Meurer
O
O
Braun-Falco
D000328:Adult; D000368:Aged; D002613:Cheilitis / Q000139:chemically induced; D002986:Clinical Trials as Topic; D005050:Etretinate / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D005050:Etretinate